FR2162268A1 - 6-alpha, 17-beta-dihydroxy-13-beta-ethyl-17-alpha - -ethynylgona-4,9,11-triene-3-one - with anti oesterogenic anti-lh and - Google Patents

6-alpha, 17-beta-dihydroxy-13-beta-ethyl-17-alpha - -ethynylgona-4,9,11-triene-3-one - with anti oesterogenic anti-lh and

Info

Publication number
FR2162268A1
FR2162268A1 FR7144012A FR7144012A FR2162268A1 FR 2162268 A1 FR2162268 A1 FR 2162268A1 FR 7144012 A FR7144012 A FR 7144012A FR 7144012 A FR7144012 A FR 7144012A FR 2162268 A1 FR2162268 A1 FR 2162268A1
Authority
FR
France
Prior art keywords
alpha
beta
ethylenedioxy
hydroxyimino
ethynylgona
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7144012A
Other languages
French (fr)
Other versions
FR2162268B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Priority to FR7144012A priority Critical patent/FR2162268A1/en
Publication of FR2162268A1 publication Critical patent/FR2162268A1/en
Application granted granted Critical
Publication of FR2162268B1 publication Critical patent/FR2162268B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C07J75/005—Preparation of steroids by cyclization of non-steroid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/16—Benz[e]indenes; Hydrogenated benz[e]indenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Abstract

(A) 6 alpha, 17 beta-dihydroxy-13 beta-ethyl-17 alpha-ethynylgona-4,9, 11-triene-3-one (I) (B) Compounds of formulae (II) (III) where in (II) Z = hydroxyimino; X = O or ethylenedioxy; R' and R2 together represent a double bond between C11 and C12; Y' is OH; Y2 is H; or Z is X is ethylenedioxy; Y' is acetoxy; Y2 is H; R' is Br; R2 is H; or R' and R2 together form a double bond between C11 and C12; in (III) Y is X is O or ethylenedioxy; Z' and Z2 are together hydroxyimino; or Y is oxo; X is ethylenedioxy; Z' and Z2 are together hydroxyimino; or Y is X is ethylenedioxy; Z' and Z2 are together hydroxyimino, acetoxyimino, or O; or Z' is alpha-OH and Z2 is H. (I) has antioestrogenic; pituitary inhibitory and anti-LH activity, and may be used in treatment of e.g. acne, seborrhoea and circulatory disorders associated with menopause. (I) and (II) are intermediates for (I). Suitable dose of (I) is 0.1 to 10 mg/day for adjlts in unit doses of 0.1 to 2mg.
FR7144012A 1971-12-08 1971-12-08 6-alpha, 17-beta-dihydroxy-13-beta-ethyl-17-alpha - -ethynylgona-4,9,11-triene-3-one - with anti oesterogenic anti-lh and Granted FR2162268A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7144012A FR2162268A1 (en) 1971-12-08 1971-12-08 6-alpha, 17-beta-dihydroxy-13-beta-ethyl-17-alpha - -ethynylgona-4,9,11-triene-3-one - with anti oesterogenic anti-lh and

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7144012A FR2162268A1 (en) 1971-12-08 1971-12-08 6-alpha, 17-beta-dihydroxy-13-beta-ethyl-17-alpha - -ethynylgona-4,9,11-triene-3-one - with anti oesterogenic anti-lh and

Publications (2)

Publication Number Publication Date
FR2162268A1 true FR2162268A1 (en) 1973-07-20
FR2162268B1 FR2162268B1 (en) 1975-02-07

Family

ID=9087121

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7144012A Granted FR2162268A1 (en) 1971-12-08 1971-12-08 6-alpha, 17-beta-dihydroxy-13-beta-ethyl-17-alpha - -ethynylgona-4,9,11-triene-3-one - with anti oesterogenic anti-lh and

Country Status (1)

Country Link
FR (1) FR2162268A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1492782A (en) * 1963-02-20 1967-08-25 Roussel Uclaf Novel unsaturated steroid derivative and method of preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1492782A (en) * 1963-02-20 1967-08-25 Roussel Uclaf Novel unsaturated steroid derivative and method of preparation

Also Published As

Publication number Publication date
FR2162268B1 (en) 1975-02-07

Similar Documents

Publication Publication Date Title
FR2162268A1 (en) 6-alpha, 17-beta-dihydroxy-13-beta-ethyl-17-alpha - -ethynylgona-4,9,11-triene-3-one - with anti oesterogenic anti-lh and
ES364982A1 (en) Iron preparation and process for its manufacture
Brohult et al. A case of multiple arterial thromboses after oral contraceptives and ergotamine
FR2271832A1 (en) Compsns. contg. sex hormones and their esters - for improving wt. gain in meat animals
GB1049996A (en) New medicine with anti-inflammatory and anti-rheumatic activity
BE783494A (en) COMPOSITION AND METHOD FOR THE TREATMENT OF PULMONARY AFFECTIONS BY MEANS OF INHALATION.
Andrews et al. Patient acceptance of oral contraception
ES362613A1 (en) 17{60 ,21-orthocarbonates of steroid derivatives
Takagi et al. The therapeutic effect of FM100, a fraction of licorice root, on acetic acid ulcer in rats
CA988418A (en) Agents for inhalation therapy of bronchial diseases
USD228219S (en) Combined egg cup and salt cellar
GB1384921A (en) Chair for concrete reinforcing elements
USD201828S (en) Stamp dispensing machine
FR2159230A1 (en) Purified extracts of cypress cones - for treatment of vascular disorders
IE36780B1 (en) New pharmaceutical preparations
KR780000519B1 (en) Technique for preparation of iron oxide films by cathodic sputtering
USD223342S (en) Portable beverage dispenser
USD163655S (en) Chair back
Ravera et al. Effects of chelating agents(EDTA and SNTA) on the incorporation of radionuclides by freshwater filter feeding organisms(copepod and lamellibranch).
USD217370S (en) Pool game tabletop
USD202864S (en) Flush valve
USD225554S (en) Hydraulic jack for prestressing concrete
FR2032598A5 (en) Continuous fermentation of molasses and - other alcohol formers
Róheim et al. Fantasies and dreams of a schizophrenic patient.
FR1510M (en) New drug in particular for the treatment of deficiencies of the corpus luteum.

Legal Events

Date Code Title Description
ST Notification of lapse